Applicants:

Kenichiro Kosai et al

Serial No. :

10/584,109

Filed

June 22, 2006

Page

2 of 8

AMENDMENTS TO THE CLAIMS

This listing of claims replaces all prior versions and listings of claims in the application:

Attorney Docket No.: 55801-003US1

Client Ref. No.: PCT04TL2

Listing of claims:

1. (Withdrawn) A drug for treating a heart disease characterized by cardiac hypertrophy or tachycardia, comprising an expression vector containing a CD9 gene as the active ingredient and a pharmaceutically acceptable auxiliary or carrier;

wherein the expression vector is a viral vector or a non-viral vector; and wherein the viral vector is an adeno-associated virus, a retrovirus, a herpesvirus, a herpes simplex virus, a lentivirus, a Sendai virus, a poxvirus, a poliovirus, a symbis virus, or a vaccinia virus.

- 2. (Cancelled)
- 3. (Withdrawn) The drug according to Claim 1, wherein the heart disease is an ischemic heart disease.
- 4. (Withdrawn) The drug according to Claim 3, wherein the ischemic heart disease is myocardial infarction.
 - 5-10. (Cancelled)
- 11. (Withdrawn) The drug according to Claim 1, wherein cardiac hypertrophy or tachycardia is caused by at least one of heparin binding epidermal growth factor (HB-EGF), hepatocyte growth factor (HGF), or angiotensin 2.

12-13. (Cancelled)

Applicants : Kenichiro Kosai et al

Serial No. :

10/584,109

Filed

June 22, 2006 3 of 8

Page

14. (Currently Amended) A method for treating a heart disease suppressing cardiac hyphertrophy or cardiac tachycardia in a subject having a heart disease, comprising administering directly to or via a coronary artery supplying a cardiac muscle in the heart of [[a]] the subject in need thereof an effective amount of an expression vector containing a sequence encoding a CD9 protein;

Attorney Docket No.: 55801-003US1

Client Ref. No.: PCT04TL2

wherein the heart disease is characterized by myocardial infarction, hypertrophy, arrhythmia, or tachycardia; and

wherein the heart disease is treated by suppressing cardiac hypertrophy or cardiac tachycardia is suppressed in the subject.

15. (Cancelled)

- 16. (Currently Amended) The method for treating a heart disease according to Claim 14, wherein the heart disease is an ischemic heart disease.
- 17. (Currently Amended) The method for treating a heart disease according to Claim 16, wherein the ischemic heart disease is myocardial infarction.

18-23. (Cancelled)

24. (Currently Amended) The method for treating a heart disease according to Claim 14, wherein cardiac hypertrophy or tachycardia is caused by at least one of heparin binding epidermal growth factor (HB-EGF), hepatocyte growth factor (HGF) or angiotensin 2.

25-28. (Cancelled)

29. (Withdrawn) The drug according to Claim 1, wherein the expression vector is a viral vector.

Applicants : Kenichiro Kosai et al

Serial No. :

10/584,109

Filed Page

: June 22, 2006 : 4 of 8

30. (Withdrawn) The drug according to Claim 1, wherein the expression vector is a non-viral vector.

Attorney Docket No.: 55801-003US1

Client Ref. No.: PCT04TL2

31-34. (Cancelled)

- 35. (Currently Amended) The method for treating a heart disease according to Claim 14, wherein the expression vector is a viral vector or a non-viral vector.
- 36. (Currently Amended) The method for treating a heart disease according to Claim 35, wherein the viral vector is an adenovirus, an adeno-associated virus, a retrovirus, a herpesvirus, a herpes simplex virus, a lentivirus, a Sendai virus, a poxvirus, a poliovirus, a symbis virus, or a vaccinia virus.
- 37. (Currently Amended) The method for treating a heart disease according to Claim 36, wherein the expression vector is adenovirus.
- 38. (Currently Amended) The method for treating a heart disease according to Claim 37, wherein the heart disease is an ischemic heart disease.
- 39. (Currently Amended) The method for treating a heart disease according to Claim 38, wherein the ischemic heart disease is myocardial infarction.
- 40. (Withdrawn) The method for treating a heart disease according to Claim 35, wherein the non-viral vector is a cationic liposome, a membrane-fusing liposome, or a cationic polymer.
- 41. (Withdrawn) The method for treating a heart disease according to Claim 40, wherein the heart disease is an ischemic heart disease.

Applicants : Serial No. :

Kenichiro Kosai et al

Filed

10/584,109 June 22, 2006 5 of 8

Page

Attorney Docket No.: 55801-003US1 Client Ref. No.: PCT04TL2

42. (Withdrawn) The method for treating a heart disease according to Claim 41, wherein the ischemic heart disease is myocardial infarction.